![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » IRIDEX Scores CE Mark for G6 Laser Treatment of Glaucoma
IRIDEX Scores CE Mark for G6 Laser Treatment of Glaucoma
February 16, 2016
IRIDEX has gained its CE Mark to sell its first laser system in Europe, which is intended to treat the multiple stages of glaucoma.
The Cyclo G6 laser system consists of a cluster of one-time use probes that links to a user-friendly consoles, and showcases the company’s tissue-saving technology.
"The Cyclo G6 is a new and effective option for those patients who have been unsuccessful with the burden of frequent administration of eye drops and do not wish to have surgical intervention or implants,” said Keith Barton, consultant ophthalmologist at Moorfields Eye Hospital.
Studies on the laser system have revealed an ability to reduce intraocular pressure by up to 40 percent without implants or surgery, according to Barton. — Anisa Jibrell
Upcoming Events
-
21Oct